Frank DAmelio - Zoetis Independent Director

ZTS -- USA Stock  

USD 122.42  2.78  2.32%

  Director
Mr. Frank A. DAmelio is Independent Director of the Company. Mr. DAmelio previously served as Pfizers Executive Vice President, Business Operations and Chief Financial Officer from December 2010 to September 2018. He joined Pfizer in September 2007 and held various positions, including Senior Vice President and Chief Financial Officer. From November 2006 to August 2007, Mr. DAmelio was the Senior Executive Vice President of Integration and Chief Administrative Officer at AlcatelLucent, S.A., a global telecommunications equipment company. Prior to the merger of Alcatel and Lucent Technologies in 2006, Mr. DAmelio was the Chief Operating Officer of Lucent Technologies, with responsibility for leading business operations, including sales, the product groups, the services business, the supply chain, information technology operations, human resources and labor relations. In 2001, he was appointed Executive Vice President and Chief Financial Officer of Lucent and in 2004 was promoted to be Executive Vice President, Chief Administrative Officer and Chief Financial Officer and helped lead the company through one of the most challenging periods in the telecom industrys history and returned the company to profitability. In this role, Mr. DAmelio was responsible for management and oversight of all financial, accounting, real estate and labor relations operations and the operational aspects of the legal and human resources organizations. Mr. DAmelio currently serves as a member of the board of Humana Inc., a health care company that offers a wide range of insurance products and health and welfare services. He also serves on the board of the Independent College Fund of New Jersey, and formerly served as a member of the National Advisory Board of JPMorgan Chase Co. Mr. DAmelio earned his MBA in Finance from St. Johns University and his bachelors degree in Accounting from St. Peters College. Mr
Age: 60  Director Since 2016  MBA    
973-822-7000  http://www.zoetis.com
D?Amelio earned his MBA in Finance from St. John?s University and his bachelor?s degree in Accounting from St. Peter?s College.

Frank DAmelio Latest Insider Activity

Management Efficiency

The company has Return on Asset of 12.56 % which means that on every $100 spent on asset it made $12.56 of profit. This is considered to be average in the sector. In the same way, it shows return on shareholders equity (ROE) of 62.6 % implying that it generated $62.6 on every 100 dollars invested.
The company has 6.65B in debt with debt to equity (D/E) ratio of 275.9 . This implies that the company may be unable to create cash to meet all of its financial commitments. Zoetis has Current Ratio of 4.09 demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due.

Similar Executives

Showing few of many executives

DIRECTOR Since

Geoffery MerszeiOrigin Agritech Limited
2016
Omkar GoswamiDr Reddys Laboratories Ltd
2000
Joseph GoldsteinRegeneron Pharmaceuticals
1991
Jacqualyn FousePerrigo Company plc
2012
William YoungVertex Pharmaceuticals Incorpor
2014
Bruce SachsVertex Pharmaceuticals Incorpor
2017
Bruce CarterDr Reddys Laboratories Ltd
2008
Lloyd CarneyVertex Pharmaceuticals Incorpor
2019
Anupam PuriDr Reddys Laboratories Ltd
2002
Alan GarberVertex Pharmaceuticals Incorpor
2017
Prasad MenonDr Reddys Laboratories Ltd
2019
Larry CordellOrigin Agritech Limited
2012
Yuchun LeeVertex Pharmaceuticals Incorpor
2012
Gary KunklePerrigo Company plc
2009
Min TangOrigin Agritech Limited
2009
Shikha SharmaDr Reddys Laboratories Ltd
2019
Christine PoonRegeneron Pharmaceuticals
2010
Rolf ClassonPerrigo Company plc
2017
George SingRegeneron Pharmaceuticals
1988
Elaine UllianVertex Pharmaceuticals Incorpor
2011
Laurie BrlasPerrigo Company plc
2016

Entity Summary

Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. The company was founded in 1952 and is headquartered in Parsippany, New Jersey. Zoetis operates under Drug Manufacturers - Specialty Generic classification in USA and is traded on BATS Exchange. It employs 10000 people.Zoetis (ZTS) is traded on BATS Exchange in USA and employs 10,000 people.

Zoetis Leadership Team

Roman Trawicki, Executive Vice President and Presidentident of Global Manufacturing and Supply
Kristin Peck, Executive Vice President and Group President, U.S. Operations, Business Development and Strategy
William Steere, Independent Director
Roxanne Lagano, Executive Vice President, Chief Human Resources Officer and Communications
Linda Rhodes, Independent Director
Frank DAmelio, Independent Director
Robert Scully, Independent Director
Clinton Lewis, Executive Vice President and Group President, International Operations, Commercial Development, Global Genetics, Aquatic Health and Human Medical Diagnostics
Stefan Weiskopf, Executive Vice President and Area President of the Asia Pacific, Australia and New Zealand
Sanjay Khosla, Independent Director
Paul Herendeen, CFO and Executive VP
Catherine Knupp, Executive Vice President, President - Research and Development
Michael McCallister, Non-Executive Independent Chairman of the Board
Paul Bisaro, Independent Director
Alejandro Bernal, Executive Vice President and Area President of the Europe, Africa and Middle East region
Willie Reed, Independent Director
Joyce Lee, Executive Vice President and Area President of the Canada and Latin America region
Glenn David, Chief Financial Officer, Executive Vice President
Sandra Beaty, Executive Vice President - Corporate Affairs
William Doyle, Director
Andrew Fenton, Executive Vice President and Chief Digital and Technology Officer
Gregory Norden, Independent Director
Louise Parent, Independent Director
Heidi Chen, Executive Vice President General Counsel, Corporate Secretary
Juan Alaix, Chief Executive Officer, Director

Stock Performance Indicators

Did you try this?

Run Portfolio File Import Now

   

Portfolio File Import

Quickly import all of your third-party portfolios from your local drive in csv format
All  Next Launch Module

Also Currentnly Active

Purchased over 20 shares of
a day ago
Traded for 15.09
Purchased few shares of
a day ago
Traded for 42.34
Purchased few shares of
a day ago
Traded for 119.16
See also Your Current Watchlist. Please also try Pattern Recognition module to use different pattern recognition models to time the market across multiple global exchanges.
Search macroaxis.com